Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

Authors:

Abstract
Aim: To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. Methods: Patients enrolled in the MS PA... Plain language summary Knowledge of treatment-related benefits associated with medication choices, including improvement of quality of life (QoL), are strong influential factors for patients to sta... Tweetable abstract Natalizumab had shorter time to clinically meaningful improvement in the Neuro-QoL domains, Cognitive Function, Sleep Disturbance, Social Role Participation and Social Role Satis...
Funding Information
  • Biogen

This publication has 23 references indexed in Scilit: